Colorectal Cancer Therapeutics Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029 Segmented By Drug Class (Chemotherapy, Immunotherapy, others), by region, and Competition

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

Forecast Period

2025-2029

Market Size (2023)

USD 11.10 billion

CAGR (2024-2029)

4.20%

Fastest Growing Segment

Immunotherapy Segment

Largest Market

North America

 

Market Overview

Global Colorectal Cancer Therapeutics Market was valued at USD 11.10 billion in 2023 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 4.20% through 2029.  Colorectal cancer, also known as colon cancer or rectal cancer, is a type of cancer that originates in the colon or rectum, which are parts of the digestive system.  The colon, also called the large intestine, is a long tube-like organ that forms the last part of the digestive system. It plays a key role in absorbing water and nutrients from the food we eat. The rectum is the final portion of the colon, connecting to the anus. Colorectal cancer typically begins as small growths or polyps on the inner lining of the colon or rectum. While most polyps are benign, some can develop into cancer over time, particularly if left untreated. Several factors can increase the risk of developing colorectal cancer. These include age (risk increases with age), family history of colorectal cancer, personal history of colon polyps, a diet high in red or processed meats, smoking, excessive alcohol consumption, and certain genetic conditions. The symptoms of colorectal cancer can include changes in bowel habits (such as diarrhea or constipation), blood in the stool, abdominal pain or cramps, unexplained weight loss, fatigue, and a feeling that the bowel does not empty completely. However, early-stage colorectal cancer may not cause noticeable symptoms.

Treatment options for colorectal cancer depend on the stage and extent of the disease. Common treatments include surgery to remove the tumor, chemotherapy, radiation therapy, targeted therapies, and immunotherapy. Treatment plans are often tailored to the individual patient's condition. Ongoing research and development efforts have led to the discovery of new and more effective treatment options, including immunotherapies, targeted therapies, and precision medicine approaches. Public health efforts and awareness campaigns promoting colorectal cancer screening and early detection have led to more cases being diagnosed at earlier, more treatable stages, driving the demand for therapeutics. Patients and their families increasingly seek advanced and innovative treatment options, influencing the demand for the latest therapies.

Key Market Drivers

Advancements in Treatment Options

Immune checkpoint inhibitors like pembrolizumab and nivolumab have shown promise in treating colorectal cancer. These drugs work by blocking certain proteins that inhibit the immune system's ability to recognize and attack cancer cells. Targeted therapies such as anti-EGFR and anti-VEGF agents have become integral to the treatment of colorectal cancer. These drugs specifically target proteins or pathways involved in cancer growth and spread. Advances in molecular profiling and genetic testing have allowed for the identification of specific genetic mutations and biomarkers in colorectal cancer. This information is used to tailor treatment plans to the individual patient, leading to more effective therapies. The development of BRAF inhibitors like encorafenib for patients with BRAF V600E-mutated colorectal cancer has provided a new treatment option for this specific subgroup of patients.

Researchers are exploring combinations of different treatments, including chemotherapy, targeted therapy, and immunotherapy, to enhance the effectiveness of treatment and overcome resistance. The use of adjuvant chemotherapy and radiation therapy before or after surgery, and neoadjuvant therapies to shrink tumors before surgery, are being optimized to improve outcomes. Liquid biopsies, which involve analyzing circulating tumor DNA in a patient's blood, are being used for early detection and monitoring of colorectal cancer. These non-invasive tests provide valuable information on disease status. Advancements in minimally invasive surgical techniques, such as laparoscopy and robotic surgery, have reduced the invasiveness of colorectal cancer surgeries, leading to quicker recovery times and reduced postoperative complications.

Physicians are increasingly developing personalized treatment plans for patients based on their unique clinical and molecular profiles. This approach considers factors like tumor stage, genetic mutations, and the patient's overall health. Improved supportive care measures, including management of side effects, and addressing the psychological and emotional needs of patients, are integral to the overall treatment of colorectal cancer. Ongoing research and clinical trials continue to explore novel therapies and treatment strategies, offering hope for further advancements in the field. This factor will help in the development of the Global Colorectal Cancer Therapeutics Market.

Rising Patient Demand for Innovative Therapies

Patients and their families have better access to information about the latest advancements in cancer treatments. They are more informed and often seek out the most current and effective therapies. Colorectal cancer patients and their loved ones naturally desire the best possible outcomes. They are often willing to explore and request innovative treatments that offer the potential for better results. Patients are becoming increasingly aware of the concept of personalized medicine, where treatment plans are tailored to their specific genetic and molecular profiles. They may request such personalized approaches to treatment.

Patient advocacy and support groups are active in disseminating information about the latest treatments and research. They often play a role in empowering patients to ask for innovative therapies. Many patients seek second opinions from multiple healthcare providers to explore all available treatment options. This can lead to the consideration of innovative therapies. Some patients actively seek opportunities to participate in clinical trials, which often involve experimental and cutting-edge treatments. Media coverage, patient testimonials, and information available on the internet can lead patients to inquire about specific treatments they have read or heard about. Patients are increasingly willing to travel to specialized cancer centers where innovative therapies are offered. Patients and advocacy groups often advocate for insurance coverage and reimbursement of innovative treatments to ensure that cost is not a barrier to access. Patients and their advocates may lobby for increased government funding and research into innovative colorectal cancer therapies. This factor will pace up the demand of the Global Colorectal Cancer Therapeutics Market.

Increasing Demand of Early Detection and Screening Initiatives

Early detection through screening allows for the identification of colorectal cancer at its earliest, most treatable stages. Patients diagnosed at an early stage often have better outcomes, which highlights the importance of early detection in reducing mortality. When colorectal cancer is detected early, less aggressive treatments like localized surgical resection may be sufficient. Early intervention can reduce the need for extensive chemotherapy and radiation therapy, making treatment more tolerable for patients. Treating colorectal cancer at an advanced stage is more costly than early-stage treatment. Early detection and intervention can help manage healthcare costs by reducing the need for extensive therapies and hospitalizations. Detecting colorectal cancer early can help preserve a patient's quality of life by minimizing the physical and emotional toll associated with advanced-stage disease and aggressive treatments.

Early detection and screening initiatives have a positive public health impact by reducing the overall burden of colorectal cancer and its associated healthcare costs. The implementation of colorectal cancer screening guidelines by healthcare organizations encourages patients to undergo regular screening, thus increasing the likelihood of early detection. Public awareness campaigns and patient education efforts promote the importance of regular screening for colorectal cancer. Informed patients are more likely to seek early detection. Healthcare providers often recommend colorectal cancer screening for eligible individuals, ensuring that patients are aware of the need for early detection. Advances in screening technologies, such as colonoscopy, fecal immunochemical tests, and CT colonography, make the process more accessible and less invasive, encouraging patient participation. Some early detection approaches involve the screening of genetic and biological markers associated with colorectal cancer. This allows for early intervention in high-risk individuals. Efforts to expand access to colorectal cancer screening, including outreach to underserved populations, contribute to early detection and subsequent demand for therapeutics among previously underserved communities. Early detection enables timely initiation of therapeutic interventions, improving the likelihood of treatment success and long-term survival. This factor will accelerate the demand of the Global Colorectal Cancer Therapeutics Market.


Download Free Sample Report

Key Market Challenges

Treatment Costs

Some of the most effective treatments for colorectal cancer, such as targeted therapies and immunotherapies, can be very expensive. The cost of these drugs can pose a substantial financial challenge for both patients and healthcare systems. In some cases, colorectal cancer treatment involves the use of multiple drugs in combination, increasing the overall cost of therapy. Colorectal cancer treatment often extends over a significant period, especially for patients with advanced or metastatic disease. The long-term nature of treatment can lead to substantial costs. While effective, traditional treatments like chemotherapy and radiation therapy can also be costly, and patients may experience side effects that necessitate additional care. Managing side effects, providing supportive care, and addressing comorbidities can add to the overall cost of treatment.

Advanced diagnostic tests, including genomic profiling and liquid biopsies, are an integral part of personalized medicine but can contribute to treatment costs. For some patients, especially those with advanced disease or complications, hospitalization and surgical procedures can incur significant expenses. Even with insurance coverage, patients often face out-of-pocket expenses, including copayments, deductibles, and coinsurance, which can be financially burdensome. Colorectal cancer treatment may result in patients taking time off work, reducing their income, and potentially leading to additional financial strain. In some regions, access to innovative and expensive treatments may be limited, potentially leading to disparities in care and outcomes. The introduction of biosimilars for biologic drugs used in colorectal cancer treatment can help reduce treatment costs. However, their availability and use may vary by region. The financial burden of cancer treatment, often referred to as "financial toxicity," can have a significant impact on a patient's overall well-being and decision-making regarding treatment choices.

Resistance to Treatment

Colorectal cancer is a heterogeneous disease, and individual tumors can have diverse genetic and molecular characteristics. This heterogeneity can make it challenging to develop effective treatments that work against all tumor subtypes. Tumors can develop resistance to treatments over time. This often occurs in response to selective pressure from therapies like chemotherapy or targeted agents. Tumor cells that survive treatment may evolve to be more resistant to subsequent therapies. While immunotherapies have shown promise in treating Microsatellite Instability (MSI-high) or DNA Mismatch Repair (dMMR) colorectal cancer, not all patients with these biomarker profiles respond. Some develop resistance to immunotherapy.

 Tumor cells can acquire secondary mutations that render them less responsive to targeted therapies, reducing the effectiveness of these treatments. Colorectal cancer cells can employ various biological mechanisms to resist treatment, including increased drug efflux, enhanced DNA repair mechanisms, and activation of survival pathways. Tumors can evade the immune system's response through mechanisms like immune checkpoint upregulation or recruitment of immunosuppressive cells. The tumor microenvironment, including the surrounding stroma and immune cells, can play a role in treatment resistance by providing a protective shield for cancer cells.  The order in which treatments are administered can affect resistance. Sequential or repetitive use of the same therapy may lead to decreased effectiveness. Each patient may develop specific mechanisms of resistance that are not always predictable, further complicating treatment strategies. Combinations of drugs with different mechanisms of action can help overcome resistance. For example, combining targeted therapies with immunotherapies may enhance treatment effectiveness.

Key Market Trends

Adjuvant Therapies

 Adjuvant therapies refer to treatments given after the primary treatment (often surgery) to reduce the risk of cancer recurrence. Adjuvant therapies, such as chemotherapy and sometimes radiation therapy, have been used to reduce the risk of cancer recurrence following surgical resection of colorectal tumors. These treatments target any remaining cancer cells that might not be visible during surgery. The use of adjuvant therapies has contributed to improved survival rates in colorectal cancer patients, especially in those with high-risk factors or advanced-stage disease. This trend has led to a better prognosis for many patients.

Adjuvant therapies are often included in personalized treatment plans based on the stage of the cancer, the presence of specific genetic mutations, and other patient-specific factors. This trend reflects the move toward tailored treatment approaches. Research has explored the optimal sequencing of adjuvant therapies, such as the timing of chemotherapy after surgery. This has the potential to improve treatment effectiveness and patient outcomes. Advances in chemotherapy agents, as well as the development of targeted therapies and immunotherapies, have expanded the options available for adjuvant treatment, providing more effective and less toxic regimens. Efforts to reduce the side effects of adjuvant therapies through targeted treatment and supportive care measures are a notable trend in improving the tolerability of these treatments. Clinical trials are ongoing to assess the benefits of new adjuvant treatments, including targeted therapies and immunotherapies, in further reducing the risk of recurrence and improving patient outcomes. Adjuvant therapies are increasingly designed to preserve patients' quality of life by minimizing treatment-related side effects and allowing for a faster return to normal activities. The introduction of biosimilars for certain adjuvant chemotherapy agents can help reduce the cost of treatment while maintaining effectiveness. Research into combination adjuvant therapies, including chemotherapy, targeted agents, and immunotherapies, is a growing trend to maximize treatment efficacy.

Segmental Insights

Drug Class Insights

In 2023, the Global Colorectal Cancer Therapeutics Market largest share was held by immunotherapy segment in the forecast period and is predicted to continue expanding over the coming years.  Immunotherapy, particularly immune checkpoint inhibitors like pembrolizumab and nivolumab, showed promise in clinical trials and research for the treatment of colorectal cancer. These therapies offered a new approach to treating the disease by harnessing the body's immune system to target cancer cells. Immunotherapies were being developed to target specific biomarkers and genetic mutations associated with colorectal cancer, such as microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) status. These therapies had the potential to be highly effective in a subset of patients. Immunotherapies were seen as a significant advancement in the treatment of refractory and advanced colorectal cancer, where other treatment options, such as chemotherapy, had limited efficacy. Positive results from clinical trials, including those presented at major medical conferences, supported the use of immunotherapies for colorectal cancer. These results often included improvements in overall survival and disease control. Researchers were exploring combination therapies that included immunotherapy, chemotherapy, and targeted therapy. These combinations showed promise in enhancing treatment response and addressing resistance issues.


Download Free Sample Report

Regional Insights

The North America region dominates the Global Colorectal Cancer Therapeutics Market in 2023. North America, particularly the United States and Canada, boasts a well-developed and advanced healthcare infrastructure. This infrastructure includes a network of world-class hospitals, research institutions, and medical centers that are at the forefront of cancer research and treatment. North America has one of the highest incidences of colorectal cancer in the world. The risk factors associated with the Western diet and lifestyle have contributed to a relatively higher prevalence of this cancer type in the region. The high incidence drives the demand for colorectal cancer therapeutics. North American healthcare systems are often early adopters of new medical technologies and therapies. This includes the adoption of novel treatments for colorectal cancer, such as immunotherapies and targeted therapies. The region is a hub for clinical trials and research in the field of oncology. It hosts numerous clinical research centers and pharmaceutical companies focused on the development of innovative colorectal cancer treatments. The availability of a vast patient pool and clinical trial infrastructure contributes to advancements in therapy. Many residents in North America have health insurance coverage, which can help in accessing costly cancer treatments. This financial support eases the burden on patients and encourages the adoption of advanced therapies.

Recent Developments

  • In January 2023, Takeda has announced an exclusive licensing agreement with HUTCHMED (China) Limited and its subsidiary, HUTCHMED Limited, for the continued development and commercialization of fruquintinib outside of mainland China, Hong Kong, and Macau. Fruquintinib, which received approval in China in 2018, is a potent inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, 2, and 3. It is orally administered and holds promise for the treatment of refractory metastatic colorectal cancer (CRC) across different biomarker statuses. Notably, positive results from the FRESCO-2 Phase 3 clinical trial, presented at the European Society for Medical Oncology (ESMO) Congress in September 2022, demonstrated that fruquintinib improved overall survival in patients with metastatic CRC and exhibited a generally well-tolerated safety profile.
  • In June 2023, Foundation Medicine Inc. has received FDA approval for the use of FoundationOne Liquid CDx as a companion diagnostic for BRAFTOVI (encorafenib) when used in combination with cetuximab. This combination is FDA-approved for adult patients with previously treated metastatic colorectal cancer (mCRC) carrying a BRAF V600E alteration. With this approval, FoundationOne Liquid CDx becomes the sole comprehensive genomic profiling (CGP) test authorized by the FDA to identify mCRC patients with BRAF V600E alterations who may benefit from treatment with BRAFTOVI and cetuximab. Pfizer's BRAFTOVI, when used alongside cetuximab, represents the first and only FDA-approved targeted therapy regimen for adults with BRAF V600E-mutated mCRC following prior therapy.

Key Market Players

  • Amgen, Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Elli and Lilly Co.
  • Merck & co., Inc.
  • F. Hoffmann-La Roche Ltd.
  • Sanofi SA

By Drug Class

By Region
  • Chemotherapy
  • Immunotherapy
  • others
  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East & Africa

 

Report Scope:

In this report, the Global Colorectal Cancer Therapeutics   Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  • Colorectal Cancer Therapeutics   Market, By Drug Class:

o   Chemotherapy

o   Immunotherapy

o   others

  • Colorectal Cancer Therapeutics   Market, By region:

o   North America

§  United States

§  Canada

§  Mexico

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Australia

§  Japan

o   Europe

§  Germany

§  France

§  United Kingdom

§  Spain

§  Italy

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

 

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Colorectal Cancer Therapeutics   Market.

Available Customizations:

Global Colorectal Cancer Therapeutics Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Colorectal Cancer Therapeutics   Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.        Markets Covered

1.2.2.        Years Considered for Study

1.2.3.        Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Clinical Trials Analysis

5.1.  Ongoing Clinical Trials

5.2.  Completed Clinical Trials

5.3.  Terminated Clinical Trials

5.4.  Breakdown of Pipeline, By Development Phase

5.5.  Breakdown of Pipeline, By Status

5.6.  Breakdown of Pipeline, By Study Type

5.7.  Breakdown of Pipeline, By Region

5.8.  Clinical Trials Heat Map

6.    Global Colorectal Cancer Therapeutics Market Outlook

6.1.  Market Size & Forecast

6.1.1.        By Value

6.2.  Market Share & Forecast

6.2.1.        By Drug Class (Chemotherapy, Immunotherapy, others)

6.2.2.        By Region

6.2.3.        By Company (2023)

6.3.  Market Map

7.    Asia Pacific Colorectal Cancer Therapeutics Market Outlook

7.1.  Market Size & Forecast

7.1.1.        By Value

7.2.  Market Share & Forecast

7.2.1.        By Drug Class

7.2.2.        By Country

7.3.  Asia Pacific: Country Analysis

7.3.1.        China Colorectal Cancer Therapeutics Market Outlook

7.3.1.1.        Market Size & Forecast

7.3.1.1.1.           By Value

7.3.1.2.        Market Share & Forecast

7.3.1.2.1.           By Drug Class

7.3.2.        India Colorectal Cancer Therapeutics Market Outlook

7.3.2.1.        Market Size & Forecast

7.3.2.1.1.           By Value

7.3.2.2.        Market Share & Forecast

7.3.2.2.1.           By Drug Class

7.3.3.        Australia Colorectal Cancer Therapeutics Market Outlook

7.3.3.1.        Market Size & Forecast

7.3.3.1.1.           By Value

7.3.3.2.        Market Share & Forecast

7.3.3.2.1.           By Drug Class

7.3.4.        Japan Colorectal Cancer Therapeutics Market Outlook

7.3.4.1.        Market Size & Forecast

7.3.4.1.1.           By Value

7.3.4.2.        Market Share & Forecast

7.3.4.2.1.           By Drug Class

7.3.5.        South Korea Colorectal Cancer Therapeutics Market Outlook

7.3.5.1.        Market Size & Forecast

7.3.5.1.1.           By Value

7.3.5.2.        Market Share & Forecast

7.3.5.2.1.           By Drug Class

8.    Europe Colorectal Cancer Therapeutics Market Outlook

8.1.  Market Size & Forecast

8.1.1.        By Value

8.2.  Market Share & Forecast

8.2.1.        By Drug Class

8.2.2.        By Country

8.3.  Europe: Country Analysis

8.3.1.        France Colorectal Cancer Therapeutics Market Outlook

8.3.1.1.        Market Size & Forecast

8.3.1.1.1.           By Value

8.3.1.2.        Market Share & Forecast

8.3.1.2.1.           By Drug Class

8.3.2.        Germany Colorectal Cancer Therapeutics Market Outlook

8.3.2.1.        Market Size & Forecast

8.3.2.1.1.           By Value

8.3.2.2.        Market Share & Forecast

8.3.2.2.1.           By Drug Class

8.3.3.        Spain Colorectal Cancer Therapeutics Market Outlook

8.3.3.1.        Market Size & Forecast

8.3.3.1.1.           By Value

8.3.3.2.        Market Share & Forecast

8.3.3.2.1.           By Drug Class

8.3.4.        Italy Colorectal Cancer Therapeutics Market Outlook

8.3.4.1.        Market Size & Forecast

8.3.4.1.1.           By Value

8.3.4.2.        Market Share & Forecast

8.3.4.2.1.           By Drug Class

8.3.5.        United Kingdom Colorectal Cancer Therapeutics Market Outlook

8.3.5.1.        Market Size & Forecast

8.3.5.1.1.           By Value

8.3.5.2.        Market Share & Forecast

8.3.5.2.1.           By Drug Class

9.    North America Colorectal Cancer Therapeutics Market Outlook

9.1.  Market Size & Forecast

9.1.1.        By Value

9.2.  Market Share & Forecast

9.2.1.        By Drug Class

9.2.2.        By Country

9.3.  North America: Country Analysis

9.3.1.        United States Colorectal Cancer Therapeutics Market Outlook

9.3.1.1.        Market Size & Forecast

9.3.1.1.1.           By Value

9.3.1.2.        Market Share & Forecast

9.3.1.2.1.           By Drug Class

9.3.2.        Mexico Colorectal Cancer Therapeutics Market Outlook

9.3.2.1.        Market Size & Forecast

9.3.2.1.1.           By Value

9.3.2.2.        Market Share & Forecast

9.3.2.2.1.           By Drug Class

9.3.3.        Canada Colorectal Cancer Therapeutics Market Outlook

9.3.3.1.        Market Size & Forecast

9.3.3.1.1.           By Value

9.3.3.2.        Market Share & Forecast

9.3.3.2.1.           By Drug Class

10. South America Colorectal Cancer Therapeutics Market Outlook

10.1.   Market Size & Forecast

10.1.1.     By Value

10.2.   Market Share & Forecast

10.2.1.     By Drug Class

10.2.2.     By Country

10.3.   South America: Country Analysis

10.3.1.     Brazil Colorectal Cancer Therapeutics Market Outlook

10.3.1.1.     Market Size & Forecast

10.3.1.1.1.         By Value

10.3.1.2.     Market Share & Forecast

10.3.1.2.1.         By Drug Class

10.3.2.     Argentina Colorectal Cancer Therapeutics Market Outlook

10.3.2.1.     Market Size & Forecast

10.3.2.1.1.         By Value

10.3.2.2.     Market Share & Forecast

10.3.2.2.1.         By Drug Class

10.3.3.     Colombia Colorectal Cancer Therapeutics Market Outlook

10.3.3.1.     Market Size & Forecast

10.3.3.1.1.         By Value

10.3.3.2.     Market Share & Forecast

10.3.3.2.1.         By Drug Class

11. Middle East and Africa Colorectal Cancer Therapeutics Market Outlook

11.1.   Market Size & Forecast

11.1.1.     By Value

11.2.   Market Share & Forecast

11.2.1.     By Drug Class

11.2.2.     By Country

11.3.   MEA: Country Analysis

11.3.1.     South Africa Colorectal Cancer Therapeutics Market Outlook

11.3.1.1.     Market Size & Forecast

11.3.1.1.1.         By Value

11.3.1.2.     Market Share & Forecast

11.3.1.2.1.         By Drug Class

11.3.2.     Saudi Arabia Colorectal Cancer Therapeutics Market Outlook

11.3.2.1.     Market Size & Forecast

11.3.2.1.1.         By Value

11.3.2.2.     Market Share & Forecast

11.3.2.2.1.         By Drug Class

11.3.3.     UAE Colorectal Cancer Therapeutics Market Outlook

11.3.3.1.     Market Size & Forecast

11.3.3.1.1.         By Value

11.3.3.2.     Market Share & Forecast

11.3.3.2.1.         By Drug Class

12. Market Dynamics

12.1.   Drivers

12.2.   Challenges

13. Market Trends & Developments

13.1.   Recent Developments

13.2.   Product Launches

13.3.   Mergers & Acquisitions

14. Global Colorectal Cancer Therapeutics Market: SWOT Analysis

15. Porter’s Five Forces Analysis

15.1.   Competition in the Industry

15.2.   Potential of New Entrants

15.3.   Power of Suppliers

15.4.   Power of Customers

15.5.   Threat of Substitute Product

16. PESTLE Analysis

17. Competitive Landscape

17.1.   Amgen, Inc.

17.1.1.     Business Overview

17.1.2.     Company Snapshot

17.1.3.     Products & Services

17.1.4.     Financials (In case of listed companies)

17.1.5.     Recent Developments

17.1.6.     SWOT Analysis

17.2.   Bayer AG

17.2.1.     Business Overview

17.2.2.     Company Snapshot

17.2.3.     Products & Services

17.2.4.     Financials (In case of listed companies)

17.2.5.     Recent Developments

17.2.6.     SWOT Analysis

17.3.   Bristol-Myers Squibb Company

17.3.1.     Business Overview

17.3.2.     Company Snapshot

17.3.3.     Products & Services

17.3.4.     Financials (In case of listed companies)

17.3.5.     Recent Developments

17.3.6.     SWOT Analysis

17.4.   Eli Lilly and Co Ltd.

17.4.1.     Business Overview

17.4.2.     Company Snapshot

17.4.3.     Products & Services

17.4.4.     Financials (In case of listed companies)

17.4.5.     Recent Developments

17.4.6.     SWOT Analysis

17.5.   Merck & co., Inc.

17.5.1.     Business Overview

17.5.2.     Company Snapshot

17.5.3.     Products & Services

17.5.4.     Financials (In case of listed companies)

17.5.5.     Recent Developments

17.5.6.     SWOT Analysis

17.6.   F. Hoffmann-La Roche Ltd.

17.6.1.     Business Overview

17.6.2.     Company Snapshot

17.6.3.     Products & Services

17.6.4.     Financials (In case of listed companies)

17.6.5.     Recent Developments

17.6.6.     SWOT Analysis

17.7.   Sanofi SA

17.7.1.     Business Overview

17.7.2.     Company Snapshot

17.7.3.     Products & Services

17.7.4.     Financials (In case of listed companies)

17.7.5.     Recent Developments

17.7.6.     SWOT Analysis

18. Strategic Recommendations

19. About Us & Disclaimer

Figures and Tables

Frequently asked questions

down-arrow

The market size of the Colorectal Cancer Therapeutics Market was estimated to be USD 11.10 billion in 2023.

down-arrow

Amgen, Inc., Bayer AG are some of the key players operating in the Colorectal Cancer Therapeutics Market.

down-arrow

Resistance to traditional chemotherapy, targeted therapies, and immunotherapies is a significant challenge.

down-arrow

There was an increasing focus on personalized treatment approaches, where therapies were tailored to a patient's specific genetic and molecular characteristics.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Colorectal Cancer Therapeutics Market to grow with a CAGR of 4.20 %

Feb, 2024

Increasing healthcare infrastructure and a supportive regulatory environment are the major drivers for the Global Colorectal Cancer Therapeutics Market.

Why Choose Us